« Back to Glossary Index

**1. Bioprospecting-Derived Resources and Products:**
– Annonin-based biopesticides from Annona squamosa
– Biofertilizers like Rhizobium
– Biopesticides such as Bacillus thuringiensis and annonins
– Veterinary antibiotics like valnemulin and tiamulin
– Derived from basidiomycete fungi Omphalina mutila and Clitopilus passeckerianus

**2. Bioremediation Products:**
– Coriolopsis gallica and Phanerochaete chrysosporium-derived laccase enzymes
– Used for treating beer factory wastewater
– Dechlorinating and decolorizing paper mill effluent

**3. Cosmetics and Personal Care Products:**
– Porphyridium cruentum-derived oligosaccharide and oligoelement blends
– Xanthobacter autotrophicus-derived zeaxanthin
– Clostridium histolyticum-derived collagenases
– Microsporum-derived keratinases

**4. Nanotechnology and Biosensors:**
– Microbial laccases used in biosensor technology
– Detect polyphenolic compounds in wine
– Lignins and phenols in wastewater

**5. Pharmaceuticals:**
– Streptomycin discovered from actinomycete Streptomyces griseus
– Antibacterial drugs like aminoglycosides, tetracyclines, cephalosporins
– Macrolides, glycopeptides, rifamycins, lincosamides, streptogramins
– Phosphonic acid antibiotics

Bioprospecting (Wikipedia)

Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example, almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.

Many important medications have been discovered by bioprospecting including the diabetes drug metformin (developed from a natural product found in Galega officinalis).

Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g. seas and oceans) and organisms (e.g. myxobacteria, archaea) as a means of identifying new compounds with novel biological activities. Species may be randomly screened for bioactivity or rationally selected and screened based on ecological, ethnobiological, ethnomedical, historical or genomic information.

When a region's biological resources or indigenous knowledge are unethically appropriated or commercially exploited without providing fair compensation, this is known as biopiracy. Various international treaties have been negotiated to provide countries legal recourse in the event of biopiracy and to offer commercial actors legal certainty for investment. These include the UN Convention on Biological Diversity and the Nagoya Protocol. The WIPO is currently negotiating more treaties to bridge gaps in this field.

Other risks associated with bioprospecting are the overharvesting of individual species and environmental damage, but legislation has been developed to combat these also. Examples include national laws such as the US Marine Mammal Protection Act and US Endangered Species Act, and international treaties such as the UN Convention on Biological Diversity, the UN Convention on the Law of the Sea, and the Antarctic Treaty.

« Back to Glossary Index